Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data RELMADA THERAPEUTICS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
1.29
2.94
7.02
7.86
36
90.6
113
54.8
46.2
26.9
General and administrative
5.93
3.97
5.7
7.25
24.9
35.1
47.9
48.9
37.7
32.2
Operating expenses
7.22
6.92
12.7
15.1
60.8
126
161
104
83.9
59.1
Operating income
-7.22
-6.92
-12.7
-15.1
-60.8
-126
-161
-104
-83.9
-59.1
Interest income
5.15
3.53
1.4
Other non-operating income
0.93
-2.04
-4.59
0.1
1.38
-0.05
4.21
4.91
3.91
1.72
Net income
-6.29
-8.96
-17.3
-15
-59.5
-126
-157
-98.8
-80
-57.4
EBITDA
-7.13
-6.91
-12.7
-15.1
-60.8
-126
EPS, basic
-2.09
-2.86
-2.74
-1.62
-3.81
-7.16
-5.30
-3.28
-2.65
-1.45
EPS, diluted
-2.09
-2.86
-2.74
-1.62
-3.81
-7.16
-5.30
-3.28
-2.65
-1.45
Shares, basic (weighted)
3
3.14
6.31
9.24
15.6
17.6
29.6
30.1
30.2
39.5
Shares, diluted (weighted)
3
3.14
6.31
9.24
15.6
17.6
29.6
30.1
30.2
39.5
Balance sheet
FY2017
FY2018
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
1.71
2.24
9.22
36.3
2.5
44.4
5.4
4.09
3.86
3.5
Short-term investments
80.2
115
167
143
92.2
41.1
89.5
Receivables
0.51
Other current assets
0.47
0.43
0.52
0.42
0.9
11.3
4.04
1.19
0.89
0.98
Total current assets
2.47
2.74
9.98
117
118
223
153
97.5
45.8
94
Property, plant and equipment
0
0.01
0.01
0.01
0
Other non-current assets
0.02
0.02
0.03
0.03
0.03
0.03
0.03
0.04
0.02
0.02
Total assets
2.84
3.05
10.2
117
118
223
153
97.6
45.8
94
Accounts payable
0.53
0.77
0.92
0.52
8.35
11.2
5.26
3.51
4.13
1.57
Accrued liabilities
0.39
0.66
1.32
0.82
4.26
3.87
7.21
8.69
6.16
4.86
Total current liabilities
1.38
5.9
2.61
1.46
12.6
15.1
12.5
12.2
10.3
6.43
Long-term debt
2.66
Total liabilities
1.38
8.56
2.61
1.46
12.6
15.1
12.5
12.2
10.3
7.49
Paid-in capital
86.8
88.8
119
236
285
513
603
646
676
785
Retained earnings
-85.4
-94.3
-112
-120
-179
-305
-462
-561
-641
-698
Shareholders' equity
1.46
-5.51
7.61
116
106
208
140
85.4
35.5
86.5
Total equity
1.46
-5.51
7.61
116
106
208
140
85.4
35.5
86.5
Total liabilities and equity
2.84
3.05
10.2
117
118
223
153
97.6
45.8
94
Shares outstanding
3.11
3.14
9.74
14.5
16.3
27.7
30.1
30.1
30.2
73.3
Cash flow statement
FY2017
FY2018
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-6.29
-8.96
-17.3
-15
-59.5
-126
-157
-98.8
-80
-57.4
Depreciation and amortization
0.09
0
0
0
0
0
Stock-based compensation
0.7
0.52
1.21
3.17
20.8
40.5
44.2
43.8
30.2
13.9
Change in receivables
-0.51
Change in payables
-0.73
0.16
0.16
0.16
7.82
2.85
0.42
-1.76
0.62
-2.56
Cash from operations
-6.47
-6
-10.5
-12.1
-27.8
-91.9
-104
-51.7
-51.8
-45.8
Capital expenditures
-0.05
-0.01
-84.8
-182
Purchases of investments
-182
-223
-47.3
-90.5
-12.1
-83.8
Cash from investing
-0.05
-0.01
-80.2
-34.4
-54.1
19.7
50.5
51.6
-48.1
Stock issued
17.8
19.8
185
42.7
0.25
93.6
Cash from financing
-0.27
6.54
17.5
126
28.5
188
45
-0.1
-0.04
93.6
Net change in cash
-6.79
0.53
6.98
33.9
-33.8
41.9
-39
-1.3
-0.23
-0.36
Free cash flow
-6.52
-6.01
-96.9
-210
Interest paid
0
0
0.01
0.01
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.83 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-30.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-28.3%
Net income / average total assets.
Return on invested capital (ROIC)
-26.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
143.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-14.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-3.9%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
105.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-15.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-4.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
30.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
10.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
20.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
29.5x
Current assets / current liabilities.
Quick ratio
29.3x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
29.3x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.41
Cash from operations / diluted weighted shares.
Book value per share
$1.94
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.98x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.98x
Market cap / tangible book value, when positive.
Earnings yield
-15.2%
Net income / market cap (the inverse of P/E).
Was RELMADA THERAPEUTICS, INC. profitable in fiscal 2025?
No. It reported a net loss of $57.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.